Bookmarks Share Print
Sickle Cell Anemia Image, Young Girl

Sickle Cell Anemia Clinical Trial NCT02961218

Novartis Pharmaceuticals is sponsoring a clinical research trial for males and females, ages 12-20 years with sickle cell anemia. 

Sickle cell anemia is found in patients who have inherited a red blood cell disorder where their red blood cells are shaped like a crescent or sickle. Because these cells are abnormally shaped, they do not last as long as normal, round blood cells; this causes anemia. These sickle cells can also get caught in blood vessels, consequently causing a blockage in blood flow. This can result in pain and organ damage.

Sickle cell anemia is the most common and severe kind of sickle cell disease. Individuals with sickle cell disease have inherited one of the two abnormal genes which causes the body to make hemoglobin S; those with sickle cell anemia have inherited two hemoglobin S genes (Hemoglobin SS).

To learn more about sickle cell anemia, click here

This study is designed to assess the effect that the drug ACZ885 has on daily pain experienced by sickle cell anemia patients. The effects of ACZ885 will be compared to the placebo drug effects.

If you are eligible and agree to participate in this study, you will receive either ACZ885 (the study drug) or a placebo (an inactive drug used to compare its effects to effects of the tested drug) during the first 6 months, and then you will have the opportunity to receive the study drug, ACZ885 for another 6 months.

To see if you may be eligible, click here for a pre-screener / questionnaire

Find out if there is a sickle cell anemia clinical study location nearby

People who participate in the trial must meet the following requirements:

  • Must be between the ages of 12-20 years old
  • Must be diagnosed with sickle cell anemia (HbSS) or sickle beta thalassemia
  • Have experienced several pain crises within the past year
  • Have not received treatment involving red blood cell transfusion therapy within the past 6 months

Patients who are eligible and decide to enroll in either trial:

  • Will be given monthly doses of either the study drug or placebo via subcutaneous injection for the trial period
  • Will not be charged to participate
  • May receive compensation for time and travel costs
  • May withdraw from the trial at any time, for any reason

To learn more about sickle cell anemia click here.

Additional study locations may be listed as they open in the future.  We encourage you to share this information via the links at the top of the page.